{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:04:40Z","timestamp":1787943880653,"version":"build-2784847793"},"reference-count":50,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clml.2024.07.004","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:30:07Z","timestamp":1722702607000},"page":"e835-e851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety, Efficacy, and Predictive Factors of Venetoclax-Based Regimens in Elderly Acute Myeloid Leukemia Patients: A Meta-Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8478-0547","authenticated-orcid":false,"given":"Zaheer","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faryal","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Jamil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Siddique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2024.07.004_bib0001","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.1097\/MS9.0000000000001189","article-title":"Prevalence of acute myeloid leukemia and its associated risk factors at a tertiary care center: a retrospective cross-sectional study","volume":"85","author":"Chaurasiya","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"10.1016\/j.clml.2024.07.004_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/asheducation-2002.1.73","article-title":"Acute myeloid leukemia","volume":"2002","author":"Giles","year":"2002","journal-title":"Hematology"},{"issue":"9","key":"10.1016\/j.clml.2024.07.004_bib0003","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2024.07.004_sbref0004","series-title":"In: StatPearls [Internet]","article-title":"Acute Myeloid Leukemia","author":"Vakiti","year":"2024"},{"issue":"6","key":"10.1016\/j.clml.2024.07.004_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jfma.2022.10.007","article-title":"Epidemiology and survival outcomes of acute myeloid leukemia patients in Taiwan: a national population-based analysis from 2001 to 2015","volume":"122","author":"Chien","year":"2023","journal-title":"J Formos Med Assoc"},{"issue":"9","key":"10.1016\/j.clml.2024.07.004_bib0006","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Appelbaum","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.07.004_bib0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"issue":"1","key":"10.1016\/j.clml.2024.07.004_bib0008","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.07.004_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.critrevonc.2016.12.004","article-title":"Frontline treatment of acute myeloid leukemia in adults","volume":"110","author":"Tamamyan","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.clml.2024.07.004_bib0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr Treat Options in Oncol"},{"key":"10.1016\/j.clml.2024.07.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720986646","article-title":"Venetoclax-containing regimens in acute myeloid leukemia","volume":"12","author":"Aldoss","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.004_bib0012","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/blood.V98.5.1312","article-title":"The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom medical research council AML11 trial","volume":"98","author":"Grimwade","year":"2001","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.07.004_bib0013","article-title":"Treatment with low-dose cytarabine in elderly patients (age 70 years or older) with acute myeloid leukemia: a single institution experience","volume":"8","author":"Heiblig","year":"2016","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.clml.2024.07.004_bib0014","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"Fenaux","year":"2009","journal-title":"J Clin Oncol."},{"issue":"12","key":"10.1016\/j.clml.2024.07.004_bib0015","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.clml.2021.07.008","article-title":"The real-life efficacy of fixed-dose hypomethylating agents in older patients with acute myeloid leukemia: a 10-year experience","volume":"21","author":"Rungjirajittranon","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2024.07.004_bib0016","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/14656566.2018.1465562","article-title":"Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia","volume":"19","author":"Michaelis","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.clml.2024.07.004_bib0017","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/leu.2014.216","article-title":"Management of older or unfit patients with acute myeloid leukemia","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.07.004_bib0018","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.07.004_bib0019","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","article-title":"Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia","volume":"28","author":"Cashen","year":"2010","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.clml.2024.07.004_bib0020","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.004_bib0021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","article-title":"Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study","volume":"53","author":"Al-Ali","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2024.07.004_bib0022","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2024.07.004_bib0023","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: an unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.07.004_bib0024","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.clml.2024.07.004_bib0025","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.clml.2024.07.004_bib0026","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2024.07.004_bib0027","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.clml.2024.07.004_bib0028","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.clml.2024.07.004_bib0029","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1258\/1355819021927674","article-title":"Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice","volume":"7","author":"Higgins","year":"2002","journal-title":"J Health Serv Res Policy"},{"issue":"7414","key":"10.1016\/j.clml.2024.07.004_bib0030","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2024.07.004_bib0031","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2022-171105","article-title":"Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score matched analysis","volume":"140","author":"Kwag","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.07.004_bib0032","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2024.07.004_bib0033","first-page":"290","article-title":"Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country","volume":"11","author":"Mirgh","year":"2021","journal-title":"Am J Blood Res"},{"issue":"2","key":"10.1016\/j.clml.2024.07.004_bib0034","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.26039","article-title":"Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study","volume":"96","author":"Pollyea","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.07.004_bib0035","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.clml.2024.07.004_bib0036","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.34608","article-title":"AVALON: the Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia","volume":"129","author":"Todisco","year":"2023","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2024.07.004_bib0037","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.07.004_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106803","article-title":"Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience","volume":"114","author":"De Bellis","year":"2022","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.clml.2024.07.004_bib0039","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.07.004_bib0040","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.07.004_bib0041","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jjco\/hyab170","article-title":"Venetoclax plus azacitidine in Japanese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy","volume":"52","author":"Yamamoto","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.07.004_bib0042","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.07.004_bib0043","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/jjco\/hyab112","article-title":"Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy","volume":"51","author":"Yamauchi","year":"2021","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.07.004_bib0044","first-page":"1837","article-title":"The efficacy and safety of venetoclax combined with demethylating agents in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"28","author":"Wei","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"26","key":"10.1016\/j.clml.2024.07.004_bib0045","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2024.07.004_bib0046","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/bloodadvances.2018015529","article-title":"Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia","volume":"2","author":"Ball","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.07.004_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106367","article-title":"Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy","volume":"93","author":"Talati","year":"2020","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.clml.2024.07.004_bib0048","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.clml.2024.07.004_bib0049","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200924","article-title":"Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia","volume":"218","author":"Stuani","year":"2021","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.clml.2024.07.004_bib0050","doi-asserted-by":"crossref","first-page":"E253","DOI":"10.1002\/ajh.25567","article-title":"Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"94","author":"Aldoss","year":"2019","journal-title":"Am J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T11:10:07Z","timestamp":1729595407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":50,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2152265024002611"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Efficacy, and Predictive Factors of Venetoclax-Based Regimens in Elderly Acute Myeloid Leukemia Patients: A Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}